Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.54 |
| ▸ | HTR2C | P28335 | 7/20 | 0.51 |
| ▸ | HTR2B | P41595 | 7/20 | 0.51 |
| ▸ | TMIGD3 | P0DMS9 | 5/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.47 |
| ▸ | TSPO | P30536 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3723804 | 0.89 | HTR2C (0.53) | ADORA3ADORA1HTR2CHTR2BTMIGD3 | |
| SCHEMBL1225047 | 0.88 | ADORA1 (0.53) | ADORA3ADORA1HTR2CHTR2BTMIGD3 | |
| SCHEMBL3729717 | 0.83 | ADORA3 (0.81) | ADORA3ADORA1HTR2BTMIGD3ADORA2A | |
| SCHEMBL1224373 | 0.79 | HTR2B (0.55) | ADORA3ADORA1HTR2CHTR2BTMIGD3 | |
| SCHEMBL21710880 | 0.76 | ADORA3 (0.65) | ADORA3ADORA1HTR2CHTR2BTMIGD3 | |
| SCHEMBL25566756 | 0.76 | ADORA3 (0.65) | ADORA3ADORA1HTR2CHTR2BTMIGD3 | |
| SCHEMBL3729633 | 0.74 | ADORA3 (0.70) | ADORA3ADORA1HTR2BTMIGD3ADORA2A | |
| SCHEMBL3798744 | 0.73 | ADORA3 (0.81) | ADORA3ADORA1HTR2CHTR2BTMIGD3 | |
| SCHEMBL24220655 | 0.72 | HRH2 (0.77) | ADORA3ADORA1HTR2CHTR2BTMIGD3 | |
| SCHEMBL14401404 | 0.72 | HRH2 (0.77) | ADORA3ADORA1HTR2CHTR2BTMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825126-B2 | Purine derivatives as A3 and A1 adenosine receptor agonists | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND H (MD) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | ADORA1, ADORA3, ADORA2A | ADORA3 2/4885ADORA1 1/4885HTR2C 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.